Sugi Predict

Sugi Predict / Compounds / SCHEMBL3218744

SCHEMBL3218744

SCHEMBL3218744

CC(C)(C)OC(=O)NC1CCN(C(=O)OCc2ccccc2)CC1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 2/20 0.56
▸ PDE4B Q07343 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ HTT P42858 1/20 0.49
▸ CYP2C19 P33261 1/20 0.48
▸ CTSL P07711 1/20 0.46
▸ KMT2A Q03164 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HSD11B1 P28845 1/20 0.45
▸ GRIN2B Q13224 3/20 0.44
▸ CYP2D6 P10635 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ GPR119 Q8TDV5 1/20 0.44
▸ STS P08842 1/20 0.44
▸ SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27440737 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL2448494 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL376621 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL3218733 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL3218754 1.00 CTSK (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL14131844 0.94 PDE4B (0.54) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL4791190 0.94 PDE4B (0.54) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL14145058 0.94 PDE4B (0.54) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL2348338 0.92 CTSK (0.58) CTSKPDE4BSMN1; SMN2NPC1RAB9A
SCHEMBL16841174 0.92 PDE4B (0.56) CTSKPDE4BSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667056-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-12-24 — — EP disclosed
US-20250163016-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) 2025-05-22 — — US disclosed
EP-4467537-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) 2024-11-27 — — EP disclosed
US-12122764-B2 IKAROS zinc finger family degraders and uses thereof GILEAD SCIENCES, INC. (US) 2024-10-22 — — US disclosed
EP-4339193-A1 COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2024-03-20 — — EP disclosed
CN-117157288-A Pyridine derivative, preparation method and application thereof 成都苑东生物制药股份有限公司 2023-12-01 — — CN disclosed
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-08-03 — — US disclosed
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-08-03 — — US disclosed
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-08-03 — — US disclosed
WO-2023142641-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 成都苑东生物制药股份有限公司 2023-08-03 — — WO disclosed
US-20090137568-A1 Tryclic Nitrogen Containing Compounds and their Use as Antibacterials GLAXO GROUP LIMITED 2009-05-28 — — US disclosed
US-7498326-B2 Compounds GLAXO GROUP LIMITED (GB) 2009-03-03 — — US disclosed
EP-1578743-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2006-11-29 — — EP disclosed
US-20060058287-A1 Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic GLAXO GROUP LIMITED (GB) 2006-03-16 — — US disclosed
US-20060041123-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2006-02-23 — — US disclosed
EP-1583537-A3 PIPERIDINE COMPOUNDS AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2005-12-14 — — EP disclosed
EP-1583537-A2 PIPERIDINE COMPOUNDS AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2005-10-12 — — EP disclosed
EP-1578743-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2005-09-28 — — EP disclosed
WO-2004058144-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2004-07-15 — — WO disclosed
WO-2004002490-A2 PIPERIDINE COMPOUNDS AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163016-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF KDM1B, KDM1A, EZH2 CTSK 3425/4885PDE4B 585/4885SMN1; SMN2 2285/4885
US-20090137568-A1 Tryclic Nitrogen Containing Compounds and their Use as Antibacterials NRDC, NACA, ASNS CTSK 1772/4885PDE4B 4784/4885SMN1; SMN2 3393/4885
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF IKZF2, IKZF1, IKZF3 CTSK 471/4885PDE4B 4751/4885SMN1; SMN2 2059/4885
US-12122764-B2 IKAROS zinc finger family degraders and uses thereof IKZF2, IKZF1, IKZF3 CTSK 1880/4885PDE4B 4830/4885SMN1; SMN2 1689/4885
US-20060041123-A1 Antibacterial agents NQO2, NRDC, IFNG CTSK 822/4885PDE4B 1435/4885SMN1; SMN2 2706/4885
US-20060058287-A1 Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic TLR1, TLR2, TLR6 CTSK 1892/4885PDE4B 2507/4885SMN1; SMN2 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.